This activity expired on November 20, 2023; credit is no longer available.

Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?

Activity Description

How are you pushing back against HCM in your practice? In PeerView’s latest CME/MOC/NCPD/CPE-certified activity, a panel of experts will present a MasterClass and Practicum on integrating cardiac myosin inhibitors into clinical practice. Learn how to apply the latest guidelines and sharpen your diagnostic skills to identify patients with HCM while hearing the latest recommendations for the individualized management of patients with obstructive HCM, including team-based collaboration. This activity also looks to the future and reviews the latest evidence for using cardiac myosin inhibitors in nonobstructive disease.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Identify the mechanism of action of cardiac myosin inhibitors in the treatment of patients with HCM
• Apply the latest recommendations and evidence-based guidance to diagnose and manage patients with HCM in a collaborative, team-based manner
• Describe the efficacy and safety of cardiac myosin inhibitors, including the ability to reduce eligibility for septal reduction therapy, to address unmet needs among patients with obstructive and non-obstructive HCM
• Collaborate with patients and clinical colleagues to better identify patients with HCM and achieve their personal goals and desired outcomes pertaining to HCM management

Target Audience

This activity has been designed to meet the educational needs of heart failure specialists, cardiovascular surgeons, general cardiologists, internal medicine physicians, family physicians, advanced practice clinicians (NPs/PAs), nurses, pharmacists, and other healthcare professionals involved in the management of HCM.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: October 21, 2022 - November 20, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

It is the policy of HFSA to ensure balance, independence, objectivity and scientific rigor in all continuing education (CE) activities, free from the appearance of or actual conflicts of interest (COI).

All individuals who serve as faculty, are on a committee, or are in a position to influence the content of a certified CE activity must disclose any relevant financial relationship that might affect the independent, unbiased development and presentation of the CE content.

Chair & Presenter
Milind Desai, MD, MBA
Haslam Family Endowed Chair in CV Medicine
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Director, Clinical Operations
Director, HCM Center
Department of Cardiovascular Medicine
Heart and Vascular Institute
Cleveland, Ohio

Milind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; and Medtronic.

Presenter
Neal K. Lakdawala, MD
Cardiovascular Genetics, Heart Failure and Cardiac Transplantation
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Neal K. Lakdawala, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Pfizer; Sarepta Therapeutics, Inc.; and Tenaya Therapeutics.

Presenter
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

Anjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Pfizer; and Renovacor, Inc.

Planner
Margery Tamas, MPH
PVI, PeerView Institute for Medical Education

Margery Tamas, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant for Fresenius Medical Care North America.

Accreditation, Credit, and Support

In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Learners should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

The Heart Failure Society of America designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the participant to earn up to 1.0 MOC contact hour(s) in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Nurses

This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America. This activity is approved for a maximum 1.0 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists

The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This event is accredited for up to 1.0 contact hours of knowledge-based CPE. ACPE Universal Activity Numbers (UAN): JA4008267-0000-22-016-H04-P.

Reciprocity

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Off-Label Disclosure

This educational activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this educational activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and The Heart Failure Society of America are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this accredited CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Heart Failure Society of America.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on November 20, 2023; credit is no longer available.

Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?

Activity Description

How are you pushing back against HCM in your practice? In PeerView’s latest CME/MOC/NCPD/CPE-certified activity, a panel of experts will present a MasterClass and Practicum on integrating cardiac myosin inhibitors into clinical practice. Learn how to apply the latest guidelines and sharpen your diagnostic skills to identify patients with HCM while hearing the latest recommendations for the individualized management of patients with obstructive HCM, including team-based collaboration. This activity also looks to the future and reviews the latest evidence for using cardiac myosin inhibitors in nonobstructive disease.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Identify the mechanism of action of cardiac myosin inhibitors in the treatment of patients with HCM
• Apply the latest recommendations and evidence-based guidance to diagnose and manage patients with HCM in a collaborative, team-based manner
• Describe the efficacy and safety of cardiac myosin inhibitors, including the ability to reduce eligibility for septal reduction therapy, to address unmet needs among patients with obstructive and non-obstructive HCM
• Collaborate with patients and clinical colleagues to better identify patients with HCM and achieve their personal goals and desired outcomes pertaining to HCM management

Target Audience

This activity has been designed to meet the educational needs of heart failure specialists, cardiovascular surgeons, general cardiologists, internal medicine physicians, family physicians, advanced practice clinicians (NPs/PAs), nurses, pharmacists, and other healthcare professionals involved in the management of HCM.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: October 21, 2022 - November 20, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

It is the policy of HFSA to ensure balance, independence, objectivity and scientific rigor in all continuing education (CE) activities, free from the appearance of or actual conflicts of interest (COI).

All individuals who serve as faculty, are on a committee, or are in a position to influence the content of a certified CE activity must disclose any relevant financial relationship that might affect the independent, unbiased development and presentation of the CE content.

Chair & Presenter
Milind Desai, MD, MBA
Haslam Family Endowed Chair in CV Medicine
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Director, Clinical Operations
Director, HCM Center
Department of Cardiovascular Medicine
Heart and Vascular Institute
Cleveland, Ohio

Milind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; and Medtronic.

Presenter
Neal K. Lakdawala, MD
Cardiovascular Genetics, Heart Failure and Cardiac Transplantation
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Neal K. Lakdawala, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Pfizer; Sarepta Therapeutics, Inc.; and Tenaya Therapeutics.

Presenter
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

Anjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Pfizer; and Renovacor, Inc.

Planner
Margery Tamas, MPH
PVI, PeerView Institute for Medical Education

Margery Tamas, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant for Fresenius Medical Care North America.

Accreditation, Credit, and Support

In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Learners should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

The Heart Failure Society of America designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the participant to earn up to 1.0 MOC contact hour(s) in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Nurses

This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America. This activity is approved for a maximum 1.0 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists

The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This event is accredited for up to 1.0 contact hours of knowledge-based CPE. ACPE Universal Activity Numbers (UAN): JA4008267-0000-22-016-H04-P.

Reciprocity

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Off-Label Disclosure

This educational activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this educational activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and The Heart Failure Society of America are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this accredited CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Heart Failure Society of America.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on November 1, 2023; credit is no longer available.

A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes

Activity Description and Educational Objectives

Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune disorder that is highly variable in clinical presentation and treatment response. Traditionally used treatments for gMG are broadly immunosuppressive, do not target pathogenic immunoglobulin G (IgG) autoantibodies, and provide insufficient symptom relief with significant side effects. Fortunately, advances in the understanding of gMG pathogenesis are leading to the development of new treatment options, including neonatal Fc receptor (FcRn) modulators such as the recently approved efgartigimod, and rozanolixizumab, which recently completed phase 3 trials. As with all new and emerging therapeutics, it is important for clinicians to remain abreast of the latest data.

At a recent live event, a multidisciplinary panel of experts compared the safety, efficacy, and tolerability of new treatment options with traditional therapies for gMG. Audience members received expert advice from the perspective of a neurologist, pharmacist, and infusion nurse, with the goal of providing their patients with individualized care through FcRn modulation therapy.

Upon completion of this activity, participants should be better able to:

• Compare safety, efficacy, and tolerability of new treatment options with traditional therapies for generalized myasthenia gravis (gMG)
• Apply an understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions
• Implement a safe administration protocol for the use of FcRn-modulating therapy that includes infusion procedures, premedications, vaccinations, and treatment cycle timing

Target Audience

This activity has been designed to meet the educational needs of neurology specialists (neuromuscular, neuroimmunology, neuro-ophthalmology, and general neurology), nurse practitioners, physician assistants, infusion nurses, pharmacists, and other clinicians involved in the management of gMG.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: October 2, 2022 - November 1, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. No one else in a position to control content has any financial relationships to disclose. All relevant financial relationships have been mitigated.

Chair & Presenter
James F. Howard Jr., MD
Professor of Neurology, Medicine and Allied Health
Department of Neurology
The University of North Carolina
Chapel Hill, North Carolina

James F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; argenx; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Regeneron Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Toleranzia AB; and UCB Inc.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; argenx; Cartesian Therapeutics, Inc.; Centers for Disease Control and Prevention; Millennium Pharmaceuticals; National Institutes of Health; Patient-Centered Outcomes Research Institute; and UCB Inc.
Other Financial or Material Support in the form of Stock dividends from General Electric Company; GlaxoSmithKline; Johnson & Johnson Services, Inc.; and Pfizer.

Presenter
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing
Optum Infusion Pharmacy
Lenexa, Kansas

Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Evolve Biologics; Grifols, S.A.; Koru Pharmaceuticals Co., LTD.; Octapharma AG; Pfizer; and Takeda Pharmaceuticals U.S.A., Inc.

Presenter

Stephanie Iyer, PharmD, CPP, BCACP
Clinical Pharmacist Practitioner, UNC Neurology Clinic
UNC Healthcare
Department of Pharmacy
Chapel Hill, North Carolina

Stephanie Iyer, PharmD, CPP, BCACP, has no financial interests/relationships or affiliations in relation to this activity.

Accreditation, Credit, and Support

The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The University of Florida College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This activity is supported by an educational grant from argenx US, Inc.

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and TBD contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-038-H01-P
Type of Activity: Knowledge

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and the University of Florida College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and the University of Florida College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on November 1, 2023; credit is no longer available.

A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes

Activity Description and Educational Objectives

Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune disorder that is highly variable in clinical presentation and treatment response. Traditionally used treatments for gMG are broadly immunosuppressive, do not target pathogenic immunoglobulin G (IgG) autoantibodies, and provide insufficient symptom relief with significant side effects. Fortunately, advances in the understanding of gMG pathogenesis are leading to the development of new treatment options, including neonatal Fc receptor (FcRn) modulators such as the recently approved efgartigimod, and rozanolixizumab, which recently completed phase 3 trials. As with all new and emerging therapeutics, it is important for clinicians to remain abreast of the latest data.

At a recent live event, a multidisciplinary panel of experts compared the safety, efficacy, and tolerability of new treatment options with traditional therapies for gMG. Audience members received expert advice from the perspective of a neurologist, pharmacist, and infusion nurse, with the goal of providing their patients with individualized care through FcRn modulation therapy.

Upon completion of this activity, participants should be better able to:

• Compare safety, efficacy, and tolerability of new treatment options with traditional therapies for generalized myasthenia gravis (gMG)
• Apply an understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions
• Implement a safe administration protocol for the use of FcRn-modulating therapy that includes infusion procedures, premedications, vaccinations, and treatment cycle timing

Target Audience

This activity has been designed to meet the educational needs of neurology specialists (neuromuscular, neuroimmunology, neuro-ophthalmology, and general neurology), nurse practitioners, physician assistants, infusion nurses, pharmacists, and other clinicians involved in the management of gMG.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: October 2, 2022 - November 1, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. No one else in a position to control content has any financial relationships to disclose. All relevant financial relationships have been mitigated.

Chair & Presenter
James F. Howard Jr., MD
Professor of Neurology, Medicine and Allied Health
Department of Neurology
The University of North Carolina
Chapel Hill, North Carolina

James F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; argenx; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Regeneron Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Toleranzia AB; and UCB Inc.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; argenx; Cartesian Therapeutics, Inc.; Centers for Disease Control and Prevention; Millennium Pharmaceuticals; National Institutes of Health; Patient-Centered Outcomes Research Institute; and UCB Inc.
Other Financial or Material Support in the form of Stock dividends from General Electric Company; GlaxoSmithKline; Johnson & Johnson Services, Inc.; and Pfizer.

Presenter
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing
Optum Infusion Pharmacy
Lenexa, Kansas

Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Evolve Biologics; Grifols, S.A.; Koru Pharmaceuticals Co., LTD.; Octapharma AG; Pfizer; and Takeda Pharmaceuticals U.S.A., Inc.

Presenter

Stephanie Iyer, PharmD, CPP, BCACP
Clinical Pharmacist Practitioner, UNC Neurology Clinic
UNC Healthcare
Department of Pharmacy
Chapel Hill, North Carolina

Stephanie Iyer, PharmD, CPP, BCACP, has no financial interests/relationships or affiliations in relation to this activity.

Accreditation, Credit, and Support

The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The University of Florida College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This activity is supported by an educational grant from argenx US, Inc.

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and TBD contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-038-H01-P
Type of Activity: Knowledge

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and the University of Florida College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and the University of Florida College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on October 28, 2023; credit is no longer available.

The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView’s latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with AML.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings
• Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features
• Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through independent medical education grants from AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-102-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Associate Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval Daver, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals, Inc.; Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; Gilead Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier Pharmaceuticals LLC; Shattuck Labs, Inc.; Syndax Pharmaceuticals, Inc.; and Trillium Therapeutics Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Fate Therapeutics; Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; NovImmune SA; Pfizer Inc.; Servier Pharmaceuticals LLC; Trillium Therapeutics Inc.; and TrovaGene, Inc. Research funding goes to institution.

Co-Chair/Planner
Amir T. Fathi, MD
Program Director, Center for Leukemia
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Amir T. Fathi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals, Inc./Servier Pharmaceuticals LLC.; Amgen Inc.; Astellas Pharma Inc.; Blueprint Medicines Corporation; Celgene Corporation/Bristol Myers Squibb; EnClear Therapies; Foghorn Therapeutics; Forma Therapeutics; Genentech, Inc.; ImmunoGen, Inc.; Ipsen Pharma; Kite Pharma; Kura Oncology, Inc.; Mablytics; MorphoSys AG; Novartis Pharmaceuticals Corporation; Orum; PureTech Health; and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from AbbVie Inc.; Agios Pharmaceuticals, Inc./Servier Pharmaceuticals LLC.; and Celgene Corporation/Bristol Myers Squibb.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on October 28, 2023; credit is no longer available.

The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView’s latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with AML.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings
• Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features
• Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through independent medical education grants from AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-102-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Associate Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval Daver, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals, Inc.; Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; Gilead Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier Pharmaceuticals LLC; Shattuck Labs, Inc.; Syndax Pharmaceuticals, Inc.; and Trillium Therapeutics Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Fate Therapeutics; Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; NovImmune SA; Pfizer Inc.; Servier Pharmaceuticals LLC; Trillium Therapeutics Inc.; and TrovaGene, Inc. Research funding goes to institution.

Co-Chair/Planner
Amir T. Fathi, MD
Program Director, Center for Leukemia
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Amir T. Fathi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals, Inc./Servier Pharmaceuticals LLC.; Amgen Inc.; Astellas Pharma Inc.; Blueprint Medicines Corporation; Celgene Corporation/Bristol Myers Squibb; EnClear Therapies; Foghorn Therapeutics; Forma Therapeutics; Genentech, Inc.; ImmunoGen, Inc.; Ipsen Pharma; Kite Pharma; Kura Oncology, Inc.; Mablytics; MorphoSys AG; Novartis Pharmaceuticals Corporation; Orum; PureTech Health; and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from AbbVie Inc.; Agios Pharmaceuticals, Inc./Servier Pharmaceuticals LLC.; and Celgene Corporation/Bristol Myers Squibb.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on October 26, 2023; credit is no longer available.

The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes

Media: Enduring Material
Activity Release Date: September 27, 2022
Activity Expiration Date: October 26, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists’ case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of MDS.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS
• Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS
• Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS
• Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-100-H01-P
Type of Activity: Knowledge

Faculty Disclosures

Co-Chair/Planner
Guillermo Garcia-Manero, MD
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
Gail J. Roboz, MD
Professor of Medicine
Director of the Clinical and Translational Leukemia Programs
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

Gail J. Roboz, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Janssen Pharmaceuticals, Inc.
Other Financial or Material Support as Consultant or Advisory Board or Data and Safety Monitoring Committee for AbbVie; Agios Pharmaceuticals Inc.; Amgen Inc.; AstraZeneca; Astellas Pharma US, Inc.; bluebird bio, Inc.; Blueprint Medicines; Bristol Myers Squibb; Catamaran; Celgene Corporation; F. Hoffmann-La Roche AG; GlaxoSmithKline; Helsinn Healthcare; Janssen Pharmaceuticals, Inc.; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Mesoblast Ltd; Novartis Pharmaceuticals Corporation; Pfizer; Syndax Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited-IRC Chair.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on October 26, 2023; credit is no longer available.

The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes

Media: Enduring Material
Activity Release Date: September 27, 2022
Activity Expiration Date: October 26, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists’ case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of MDS.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS
• Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS
• Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS
• Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-100-H01-P
Type of Activity: Knowledge

Faculty Disclosures

Co-Chair/Planner
Guillermo Garcia-Manero, MD
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
Gail J. Roboz, MD
Professor of Medicine
Director of the Clinical and Translational Leukemia Programs
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

Gail J. Roboz, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Janssen Pharmaceuticals, Inc.
Other Financial or Material Support as Consultant or Advisory Board or Data and Safety Monitoring Committee for AbbVie; Agios Pharmaceuticals Inc.; Amgen Inc.; AstraZeneca; Astellas Pharma US, Inc.; bluebird bio, Inc.; Blueprint Medicines; Bristol Myers Squibb; Catamaran; Celgene Corporation; F. Hoffmann-La Roche AG; GlaxoSmithKline; Helsinn Healthcare; Janssen Pharmaceuticals, Inc.; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Mesoblast Ltd; Novartis Pharmaceuticals Corporation; Pfizer; Syndax Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited-IRC Chair.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on August 17, 2023; credit is no longer available.

Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?

Media: Enduring Material
Activity Release Date: August 18, 2022
Activity Expiration Date: August 17, 2023
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis.

Target Audience

This activity has been designed to meet the educational needs of pediatricians, pediatric specialists in dermatology and allergy/immunology, primary care physicians, NPs, PAs, nurses, pharmacists, and other clinicians involved in the management of patients with atopic dermatitis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD)
• Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD
• Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD
• Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD
• Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Robert Sidbury, MD, MPH
Professor, Department of Pediatrics
Chief, Division of Dermatology
Seattle Children's Hospital
University of Washington School of Medicine
Seattle, Washington

Robert Sidbury, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for LEO Pharma Inc.
Grant/Research Support from Galderma Laboratories, L.P.; Regeneron Pharmaceuticals Inc.; and UCB, Inc.
Speakers Bureau participant with Beiersdorf, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-033-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on August 17, 2023; credit is no longer available.

Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?

Media: Enduring Material
Activity Release Date: August 18, 2022
Activity Expiration Date: August 17, 2023
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis.

Target Audience

This activity has been designed to meet the educational needs of pediatricians, pediatric specialists in dermatology and allergy/immunology, primary care physicians, NPs, PAs, nurses, pharmacists, and other clinicians involved in the management of patients with atopic dermatitis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD)
• Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD
• Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD
• Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD
• Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Robert Sidbury, MD, MPH
Professor, Department of Pediatrics
Chief, Division of Dermatology
Seattle Children's Hospital
University of Washington School of Medicine
Seattle, Washington

Robert Sidbury, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for LEO Pharma Inc.
Grant/Research Support from Galderma Laboratories, L.P.; Regeneron Pharmaceuticals Inc.; and UCB, Inc.
Speakers Bureau participant with Beiersdorf, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-033-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView